These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 23060265)
1. Vemurafenib: the first drug approved for BRAF-mutant cancer. Bollag G; Tsai J; Zhang J; Zhang C; Ibrahim P; Nolop K; Hirth P Nat Rev Drug Discov; 2012 Nov; 11(11):873-86. PubMed ID: 23060265 [TBL] [Abstract][Full Text] [Related]
2. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A; Cohen MS Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499 [TBL] [Abstract][Full Text] [Related]
3. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
6. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib. Value unclear in metastatic melanoma. Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092 [TBL] [Abstract][Full Text] [Related]
9. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067 [TBL] [Abstract][Full Text] [Related]
10. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Martin-Liberal J; Larkin J Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114 [TBL] [Abstract][Full Text] [Related]
11. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. da Rocha Dias S; Salmonson T; van Zwieten-Boot B; Jonsson B; Marchetti S; Schellens JH; Giuliani R; Pignatti F Eur J Cancer; 2013 May; 49(7):1654-61. PubMed ID: 23481513 [TBL] [Abstract][Full Text] [Related]
12. Vemurafenib: in unresectable or metastatic melanoma. Keating GM BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753 [TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633 [TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
16. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972 [TBL] [Abstract][Full Text] [Related]
17. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Swaika A; Crozier JA; Joseph RW Drug Des Devel Ther; 2014; 8():775-87. PubMed ID: 24966667 [TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Spagnolo F; Ghiorzo P; Queirolo P Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of metastatic melanoma with BRAF inhibitors]. Hafner C Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388 [No Abstract] [Full Text] [Related] [Next] [New Search]